Abstract:Objective: To explore the application of ketamine in patients with traumatic severe craniocerebral injury and analyze the changes in serum neurotrophic factor levels. Methods: A total of 180 patients with traumatic severe craniocerebral injury treated in our hospital from January 2020 to January 2023 were selected as the research objects and divided into two groups, with 90 cases in each group, according to the random number table method. The control group received single sufentanil drug treatment after surgery, while the study group received ketamine treatment based on the control group. The pain score, agitation score, cognitive function (MoCA scale), and changes in serum neurotrophic factors (BDNF, NGF) and inflammatory factors (hs-CRP, TNF-α, IL-6) at different time points were observed in both groups.Results: At 12h and 24h after administration, the pain scores and agitation scores in both groups were lower than before administration, and the scores in the study group were lower than those in the control group at 12h and 24h after administration. The MoCA scores in both groups decreased after administration, with the study group higher than the control group. Both BDNF and NGF levels increased after administration in both groups, with the study group higher than the control group. The levels of hs-CRP, TNF-α, and IL-6 decreased in both groups after administration, with the study group lower than the control group (P<0.05).Conclusion: The application of ketamine in patients with traumatic severe craniocerebral injury can effectively reduce pain and agitation scores, improve cognitive function, promote the generation of neurotrophic factors, and reduce the level of inflammatory factors.
施冬冬, 廖兴志, 陈湉, 乔燕, 肖骥峰, 刘宇芳. 艾司氯胺酮在创伤性重型颅脑损伤患者中的应用及其血清神经因子水平变化分析[J]. 河北医学, 2024, 30(6): 1044-1048.
SHI Dongdong, LIAO Xingzhi, CHEN Tian, et al. Application of Esketamine in Patients with Traumatic Severe Brain Injury and Analysis of Changes in Serum Neurofactor Levels. HeBei Med, 2024, 30(6): 1044-1048.